European Medicines Agency
*Veterinary Medicines and Inspections*

London, 13 February 2008
EMEA/CVMP/138988/2008

**PUBLIC STATEMENT ON**

**Advasure**

**(Classical Swine Fever Virus (CSFV) - E2 subunit antigen)**

## WITHDRAWAL OF THE MARKETING AUTHORISATION IN THE EUROPEAN UNION

The Committee for Medicinal Products for Veterinary Use noted that on 6 February 2008 the European Commission issued a decision to withdraw the marketing authorisation for **Advasure**. Pursuant to this decision the European Public Assessment Report for Advasure will be updated to reflect that the marketing authorisation is no longer valid. The marketing authorisation holder responsible for Advasure is Pfizer Animal Health. Advasure (previously called Bayovac CSF E2) is used to immunise pigs from the age of 2 weeks onwards to prevent death and to reduce clinical signs of classical swine fever. It is also used to reduce infection with classical swine fever and excretion of classic swine fever virus into the environment.

The European Commission was notified by the marketing authorisation holder on 4 January 2008, of its decision to voluntarily withdraw the marketing authorisation for Advasure for commercial reasons. Therapeutic alternatives are available throughout the European Union.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47
E-mail: mail@emea.europa.eu http://www.emea.europa.eu